[3.31 Updated] PhRMA: Helping those affected by the coronavirus

[331日更新] PhRMA: 守护受冠状病毒疫情影响的人群

By Stephen J. Ubl

作者:Stephen J. Ubl

Below is a snapshot of on-going PhRMA member company efforts to support the detection, prevention and treatment of the coronavirus outbreak. The below only represents a portion of the more than 50% of PhRMA’s members who are engaged in this effort.

超过一半的PhRMA成员公司都在积极为协助发现、预防和治疗冠状病毒而努力。以下为PhRMA成员公司行动的部分总结:

AbbVie: The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19. AbbVie is supporting clinical studies and basic research with lopinavir/ritonavir, working closely with European health authorities and the FDA, CDC, NIH and BARDA to coordinate on these efforts. Along with industry partners, the company has joined the Innovative Medicines Initiative to support research and discovery of targeted medicines against COVID-19. The company previously donated approximately $2 million (USD) of Aluvia as an experimental option to help address the growing health crisis. AbbVie is also working with the WHO to ensure a coordinated global effort.

艾伯维:艾伯维正在与全球多个卫生部门和医疗机构合作,研究克力芝(洛匹那韦/利托那韦)的抗新冠病毒活性以及其用于治疗COVID-19的有效性和安全性。该公司与部分欧洲卫生部门以及FDA、CDC、NIH和美国生物医学高级研究与发展管理局(BARDA)开展紧密协作,支持克力芝 (洛匹那韦/利托那韦)的临床研究与基础研究。艾伯维还加入欧洲创新药物计划,与行业合作伙伴共同支持COVID-19的靶向药物研发。此前,该公司向中国捐赠了价值约200万美元的克力芝作为试验性药物,助力解决日益增长的疫情防控需求。此外,艾伯维还积极与WHO沟通,支持协调国际抗疫合作。

Alkermes: As a leader in mental health, Alkermes recognizes there are many people who will be disproportionally impacted by COVID-19 — particularly some of the most vulnerable members of society. Alkermes has made donations to five organizations in the local communities where it operates. These organizations focus on delivering food and support for low-income families and children, as well as seniors:

  • Council on Aging and the Wilmington School District, two essential communities during this time of need (Ohio)
  • Healthy Waltham, an organization providing food to children who normally depend on meals in schools and to seniors so they can remain at home and safe during this crisis (Massachusetts)
  • ALONE, a program focused on caring for the elderly population during this vulnerable and isolating period (Ireland)
  • Feeding America’s COVID-19 Response Fund, the largest hunger-relief organization in the United States (U.S. field-based employees)

尔凯默斯:作为精神健康领域的领先企业,阿尔凯默斯意识到,很多人会不同程度地受到新冠肺炎疫情的影响,特别是社会中一些最脆弱的群体。阿尔凯默斯已向其经营所在地的五个组织捐款。这些组织致力于为低收入家庭和儿童以及老人提供食物和相关支持:

  • 年理事会威尔明顿学区。在这一时期急需关注的两个重要社区(俄亥俄州)
  • 健康沃尔瑟姆。该组织为通常在学校用餐的儿童以及老人提供食物,以便他们在这一公共卫生危机中可以安全地待在家里(马萨诸塞州)
  • ALONE该项目致力于服务在这一特殊时期需要照顾的老人(爱尔兰)
  • 消除美国饥饿组织的COVID-19应急基金该组织是美国最大的饥饿救济组织(美国驻地员工)

Amgen: Amgen and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen’s U.S. and international communities, patient-focused organizations that are mounting their own response efforts and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation will also match donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts.

安进:安进与安进基金会宣布了一项高达1250万美元的初始承诺捐款,以助力全球范围内的新型冠状病毒防控工作,驰援受疫情影响的社区,支持满足这些社区的重要需求。 该款项将用于支持安进在美国及全球其他社区开展的应急抗疫工作,患者组织的疫情防控项目,以及国际直接援助组织(Direct Relief)与国际医疗队(International Medical Corps)的国际救援工作。同时,安进基金会还将根据安进全球员工个人的捐赠情况,进行匹配捐赠。

AstraZeneca: Through its scientific expertise in infectious disease and proprietary antibody discovery technology, AstraZeneca has rapidly mobilized its research efforts to discovering novel coronavirus-neutralising antibodies as a treatment to prevent COVID-19 disease. The company is currently tailoring its Pandemic Prevention Platform (P3) program, funded in part by the U.S. government, to address the 2019-nCoV outbreak and AstraZeneca’s teams are now focused on identifying monoclonal antibodies to progress into clinical trial evaluation. AstraZeneca is also donating nine million face masks to support health care workers around the world as they respond to the COVID-19 global pandemic. The company has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organization, to identify countries in greatest need. Italy will receive the first shipments the week of March 23, with other countries to follow. In addition to these donations, AstraZeneca is accelerating the development of its diagnostic testing capabilities to scale-up screening and is also working in partnership with governments on existing screening programs to supplement testing. To help ensure the continued supply of its medicines to patients, AstraZeneca will screen employees across its manufacturing and supply network. The company’s research and development teams have also been working expeditiously to identify monoclonal antibodies to progress towards clinical trial evaluation as a treatment to prevent COVID-19. More than 50 virology, immunology, respiratory and protein engineering experts across research, clinical, regulatory and manufacturing are placing the highest priority on developing a treatment to minimize the global impact of the disease.

阿斯利康(AstraZeneca):阿斯利康借助其在传染病治疗和特异性抗体发现技术方面的专业知识,迅速动员研究力量,开发新型冠状病毒中和抗体,用于预防COVID-19疾病。目前,该公司正在调整其由美国政府部分资助的大流行病预防平台(Pandemic Prevention Platform,P3)项目,以支持新冠肺炎疫情防控。此外,阿斯利康团队还在重点开展单克隆抗体研发,以推动成果进入临床试验评估阶段。阿斯利康还向全球医护人员捐赠900万只口罩,以支持他们应对COVID-19的全球大流行。此外,阿斯利康携手由世界卫生组织(WHO)支持、世界经济论坛(WEF)发起的“应对新冠病毒行动平台”,以识别最急需支援的国家。意大利预计于3月23日当周首先收到第一批货物,其他国家也将陆续收到货物。此外,阿斯利康还将加快其在COVID-19诊断检测能力方面的开发,以帮助扩大筛查范围,并且与政府合作以在现有筛查计划以外提供补充检测支持。为了确保持续向患者提供药物,阿斯利康将为其生产和供应岗位上的员工进行新冠感染筛查。该公司研究团队目前正在合力研究对抗COVID-19病毒的单克隆抗体,并期望能够尽早进入临床试验评估,成为预防新冠的疗法,以最大程度地降低疾病带来的全球负面影响。该项目作为研发的重中之重,汇集超过50位来自研究、临床、监管、生产等领域的病毒学、免疫学、呼吸领域和蛋白质工程的专家。

Bayer: Bayer is donating 3 million tablets of the drug Resochin (chloroquine phosphate) to the U.S. Government to support its efforts in the fight against COVID-19. Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, may have potential in treating patients with COVID-19 infection, based on new and limited data from initial preclinical and evolving clinical research conducted in China. Bayer has also made a $250,000 commitment to the Berkeley Relief Fund, an initiative by the Berkeley, California, City Council to provide emergency relief grants for small businesses, nonprofit arts organizations and worker rent support. In addition, Bayer has provided substantial financial donations and donations of several medicines to the Chinese Red Cross, which is working with Chinese health authorities to coordinate the deployment of aid measures to support those affected by the outbreak of COVID-19 there. Bayer is also supporting hospitals in Lombardy, Italy, with a donation of one million euros. The aid is being added to an aid fund that the regional authorities in Lombardy have set up to help procure urgently needed equipment for intensive care units in hospitals with the greatest needs. Bayer will continue to provide affected regions and countries with rapid and unbureaucratic assistance as part of its corporate social responsibility.

拜耳:拜耳向美国政府捐赠了300万片磷酸氯喹(Resochin)药物以支持抗疫。Resochin是拜耳公司1934年研发的一款防治疟疾的药物,在中国临床前研究及正在进行的临床试验产生的少量新证据显示,它可能具有治疗新冠感染的潜力。拜耳还向伯克利救助基金会(Berkeley Relief Fund)捐款25万美元,该基金会由加利福尼亚州伯克利市议会发起,旨在为小型企业、非营利性艺术组织和工人租金支持提供紧急救济金。此外,拜耳还向中国红十字会捐赠了大量资金及医药物资,中国红十字会负责与中国政府卫生部门合作、协调部署援助措施,帮助受疫情影响的地区。拜耳还向意大利伦巴第所在医院捐款100万欧元,这笔款项已进入伦巴第地区当局设立的援助基金中,用于帮助需求最大的医院采购急需的重症监护设备。作为企业社会责任的一部分,拜耳将继续向受影响地区和国家提供快速切实的援助。

Biogen: The Biogen Foundation has committed $10 million to support global response efforts and communities around the world impacted by the COVID-19 pandemic. The funds will be used to address immediate critical needs, with the majority of donations going to support non-profit organizations in the U.S., including Massachusetts and North Carolina, in Italy and in other impacted countries worldwide. This donation will be used to help expand testing options, ease the strain on medical systems, provide training for front line health workers and support access to necessities like food. This adds to the donation made by Biogen China to the Red Cross Society of China. The company has also provided medical equipment and supplies to Partners HealthCare in Massachusetts, to help diagnose COVID-19 in a greater number of people. Partners HealthCare is one of the largest providers of healthcare services in the Boston area. Biogen will also be supporting Massachusetts General Hospital and Brigham and Women’s Hospital directly as they work on the front line to treat and contain the virus.

渤健:渤健基金会决定捐赠1000万美元,支持全球新冠大流行抗疫工作。这笔款项将用于满足最迫切的需求,其中大部分将支持美国马萨诸塞州和北卡罗来纳州、意大利以及其他受疫情影响国家的非盈利组织,以帮助这些地区扩大检测人群,缓解医疗系统压力,为一线卫生工作者提供培训,以及提供食物等必需品。此前,渤健中国已向中国红十字会捐款。此外,公司也已向美国马萨诸塞州、波士顿地区其中一家最大的医疗服务提供商Partners HealthCare提供医疗设备及物资,以帮助扩大新冠肺炎病毒的检测覆盖人群。公司还将向麻省总医院和布莱根妇女医院直接提供支持,帮助一线医务工作者治疗、控制新冠病毒感染。


Boehringer Ingelheim: Boehringer Ingelheim (BI) is standing together with all parties to support the fight against the COVID-19  pandemic while taking action to protect employees’ health and safety.  BI is continually assessing what additional measures they can take to help its patients and communities. The company’s focus remains on assuring the ongoing supply of BI medicines for its human and animals patients in the U.S. and around the world. In addition, BI has made a number of financial contributions totaling over $1 million to protect health care professionals in the critical services they are providing to patients. BI has donated medicines and medical supplies. Its teams are conducting a computational screen of our entire library of over one million compounds and are investigating the activity of selected existing small molecule compounds from our former antiviral research against SARS-CoV2. 

At a local level, BI is redeploying the hard-working employees who support its U.S. cafeterias to prepare meals to donate to those whose access to food is a struggle. The company’s U.S. Boehringer Ingelheim Cares Foundation (BI Cares), an independent nonprofit organization, is making monetary donations and donating urgently needed medicines for patients through our non-governmental organization (NGO) partners. The Foundation has made changes in its charitable Patient Assistance Program to assure the eligible U.S. patients enrolled in the program can remain adherent to the treatment they need for their medical conditions. BI Cares added a new cause to its Matching Gifts Program to provide BI U.S. employees the opportunity to double the impact of their charitable giving to a fund being used to prevent the spread of and help those affected by COVID-19. Additionally, the Foundation is conducting employee engagement campaigns to raise funds to donate to nonprofits near our U.S. sites that are distributing groceries to food insecure individuals and families.  

勃林格殷格翰:勃林格殷格翰正与各方一起支持抗击疫情,并已采取许多措施全力保障员工健康安全。勃林格殷格翰一直在考虑如何提供更多措施来帮助其患者和社区。目前,该公司的重点仍然是确保持续为人体和动物试验、以及美国和世界各地的患者提供药物。此外,勃林格殷格翰已经捐款超过100万美元,用于为前线医护人员提供更好的保护,并捐赠药品和医疗物资。该公司团队还在涵盖超过100万种化合物的整个分子库中开展筛选工作,旨在找出有望对抗病毒的潜在分子。并对过往抗病毒研究中挑选的小分子化合物的进行抗新冠病毒活性研究。

在美国,勃林格殷格翰正在重新部署美国公司的餐厅工作人员,准备食物捐赠。勃林格殷格翰关爱基金会(BI Cares)是一个独立的非营利组织,它正在联合其他非政府组织合作伙伴进行筹款,为患者捐赠急需药物。基金会调整了患者援助计划,以确保参加援助计划的美国患者可以继续接受所需治疗。BI Cares还在其捐赠匹配项目中增加了新计划,通过这个计划,员工捐赠用于抗疫的善款可以获得翻倍。此外,基金会正在开展员工活动,筹集资金捐赠给在美国公司所在地的非营利组织,支持这些组织将食物分发给困难个人和家庭。

Bristol Myers Squibb: Bristol Myers Squibb and the Bristol Myers Squibb Foundation, a 501(c)(3) organization, are actively and separately contributing to the fight against COVID-19. To date, more than $5 million in financial support and needed products has been provided to relief efforts in affected areas around the world, including the U.S., China, Italy and Greece. Both entities have increased efforts in recent weeks at the global and local levels, providing funds for personal protection equipment (PPEs) for front line health care workers, supporting patient advocacy organizations, and accelerating grant distributions to small community-based organizations that serve vulnerable populations. For more details, please visit here.

百时美施贵宝:百时美施贵宝(BMS)和百时美施贵宝基金会都分别为抗疫做出积极贡献。 迄今为止,他们已经为美国、中国、意大利和希腊等世界范围内的受灾地区提供了超过500万美元的现金和所需物资支持。 这两个组织最近几周在全球和地区层面都加大了援助力度,他们为一线卫生工作者提供购买个人防护物资(PPE)的资金支持,支援患者倡导组织,并加快向为弱势群体服务的小型社区组织拨款分配。更多详情,请访问此处

Eisai, Inc.: Eisai, Inc. has donated PPE to Hackensack Meridian Health in New Jersey and the Kaiser Health System in California. In addition, Eisai has provided funds to fast-acting patient advocacy organizations who are getting relief to patients in need.

卫材集团:卫材集团已向新泽西州的Hackensack Meridian Health和加利福尼亚的Kaiser Health系统捐赠个人防护物资(PPE)。此外,卫材还向帮助积极开展行动的患者倡导组织提供资金,用于帮助有需要的患者。

Eli Lilly and Company: Lilly is committed to doing everything possible to bring the full force of their scientific and medical expertise to attack the coronavirus pandemic. The company announced it has entered into an agreement with AbCellera to co-develop antibodies for the potential treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly’s global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies. The company also announced its scientists are partnering with the Indiana State Department of Health (ISDH), with support from the FDA, to accelerate testing in Indiana for SARS-CoV-2, the virus that causes COVID-19. Lilly will use its specialized research laboratories to analyze samples taken in Indiana health care facilities, including nursing homes and emergency rooms. Assuming the company can continuously access required diagnostic reagents, this should start to expand the state’s ability to conduct testing and receive a timely diagnosis of individuals who suspect they may be carrying the virus. As Lilly’s testing capacity expands, Lilly and ISDH will work together to maximize the impact of broader testing. Lilly is also closely monitoring their supply chain and does not currently anticipate shortages for any of their medicines, including all forms of insulin. Additionally, Lilly and the Lilly Foundation are actively engaged with community partners to address new and complex challenges arising from the coronavirus, including the economic impact on vulnerable people. Find the latest information on Lilly’s efforts here.

Eli Lilly and Company礼来公司发挥其科学和医学专业知识的全部力量,尽其所能对抗新冠病毒大流行。该公司已宣布与抗体平台AbCellera达成协议,共同开发抗体,用于治疗和预防新型冠状病毒引起的疾病。这项合作将借助大流行快速应对平台(该平台在DARPA大流行预防平台(P3)计划中开发),以及礼来在全球范围内快速开发,制造和分发治疗性抗体的能力,共同抗疫。该公司还宣布,在FDA的支持下,礼来的科学家正在开展与印第安纳州卫生部(ISDH)的合作,加快印第安纳州内新冠病毒检测。礼来公司将利用其专业研究实验室,分析在印第安纳州医疗机构(包括疗养院和急诊室)采集的样本。若公司可持续获取所需的诊断试剂,这将提升该州进行检测的能力,并为疑似携带病毒的个人提供及时的诊断。随着礼来检测能力的提升,礼来将与印第安纳州卫生部一起,使检测的效果最大化。礼来公司还将密切监测其供应链情况,目前预计不会出现包括各种形式的胰岛素在内的药品短缺。此外,礼来公司和礼来基金会也积极与社区合作伙伴合作,应对新冠病毒带来的全新复杂挑战,包括弱势群体所经受的经济影响。在此处查找有关礼来公司的最新信息。

EMD Serono: As part of the global effort to investigate potential therapeutics for COVID-19 and their support of independent research, Merck KGaA, Darmstadt, Germany* recently donated a supply of interferon beta-1a (Rebif®) to the French Institut National de la Santé et de la Recherche Médicale (INSERM) following a request for use in a clinical trial. To date, Merck KGaA, Darmstadt, Germany’s interferon beta-1a is not approved by any regulatory authority for the treatment of COVID-19 or for use as an antiviral agent.  The company has also supported China’s fight against the coronavirus with multiple donation efforts in cash and kind to three well respected local charitable organizations in order to support much needed medical aid. This includes products to support local institutions and invitro diagnostic manufactures to accelerate research, as well as virus diagnosis and testing efforts and personal protective equipment.  Overall, the spread of the coronavirus also stresses the importance of pandemic preparedness – a topic that we continue to support with our € 1 million Future Insight Prize.  *The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada.

默克雪兰诺:作为全球参与研究COVID-19潜在疗法及支持独立研究的一份子,德国达姆施塔特的默克公司(Merck KGaA)最近向法国国立医学与科学研究所(INSERM)捐赠了干扰素beta-1a(Rebif®),回应将其用于临床试验的请求。目前为止,德国达姆施塔特的默克股份公司的干扰素beta-1a还没有被监管机构批准用于治疗COVID-19或用作抗病毒剂。该公司还曾支援中国抗击新冠病毒,它向三个声誉良好的地方慈善组织捐赠了现金及多种物资,以提供急需的医疗援助,其中包括帮助本地机构和体外诊断制造商加速研究的产品,助力病毒诊断和检测的物资、和个人防护物资。总体而言,新冠病毒的传播再次强调了传染病大流行防范的重要性,默克雪兰诺将提供100万欧元的“未来洞察力奖”,继续支持这方面的努力。

*注:总部位于德国达姆施塔特的默克生物制药业务在美国和加拿大均以默克雪兰诺的身份运营。

Genentech, a member of the Roche Group: On March 23, 2020, Genentech announced the FDA approved the initiation of the company’s randomized, double-blind, placebo-controlled Phase III clinical trial (COVACTA) in collaboration with BARDA, a part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate the safety and efficacy of Actemra® (tocilizumab) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care. This is the first global study of Actemra in this setting and the company is working as quickly as possible to enroll 330 patients globally, including the United States.  Learn more about the COVACTA clinical trial here. Additionally, Genentech is providing 10,000 vials of Actemra to the U.S. Strategic National Stockpile for potential future use at the direction of the U.S. Department of Health and Human Services (HHS).  

On March 12, 2020, Roche received FDA Emergency Use Authorization for the cobas® SARS-CoV-2 Test to detect the novel virus that causes COVID-19 disease. Hospitals and reference laboratories can run the test on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems, which are widely available in the U.S. and around the world. They expect to supply about 400,000 tests per week or 1.5 million tests per month to the U.S. – and more than 3 million globally. Learn more here.

Genentech is donating $7 million to organizations dedicated to providing emergency public health response, food assistance, housing and care for the most vulnerable in our communities. These donations will be directed on a national, regional and local level. In addition, they are making significant financial donations to organizations like Direct Relief that are working locally and nationally to provide personal protective equipment (PPE), such as face masks, goggles and gowns and other critical support to health care systems.

For more see here.

基因泰克(罗氏集团成员):2020年3月23日,基因泰克宣布美国食品药品监督管理局(FDA)批准通过该公司和生物医学高级研究与开发管理局(BARDA)联合进行的随机、双盲、安慰剂对照的III期临床试验(COVACTA),该试验将对比雅美罗®(托珠单抗)联合标准疗法和安慰剂联合标准疗法,评估其新冠重症成年住院患者的有效性及安全性。BARDA隶属于美国卫生与人类服务部的防备与响应助理部长(ASPR)办公室。这是全球首个雅美罗针对新冠病毒的研究。该公司正尽快在美国在内的全球范围内招募330名患者。在此处了解有关COVACTA临床试验的更多信息。此外,基因泰克还向美国国家战略储备提供了10,000瓶雅美罗,以供未来在美国卫生与公共服务部(HHS)的指示下使用。

2020年3月12日,罗氏cobas®新冠病毒检测(cobas® SARS-CoV-2 Test)获得了FDA紧急使用授权,用于检测导致新冠肺炎的新型病毒。医院和参考实验室可以在罗氏的全自动cobas®6800和cobas®8800分析系统上进行检测,这两种分析系统在美国和世界各地都可以广泛获取。他们(罗氏)预计将每周向美国提供约40万次检测,或每月向美国提供150万次检测,全球范围内将提供300万次以上检测。在此处了解更多情况。

基因泰克将为社区中最弱势群体提供700万美元的捐赠,用于公共卫生应急响应,食品援助,住房和护理服务。这些捐款将直接用于国家、区域和地方各级。此外,他们还向国际直接援助组织(Direct Relief)一类的组织大量捐款,这些组织将在地方和全国范围内开展工作,以提供口罩、护目镜、隔离衣等个人防护物资及其他对医疗卫生系统的重要支持。有关更多信息,请参见此处

Gilead Sciences: Gilead is committed to collaborating with global health organizations to support pandemic responses. The company is working with government and non-government organizations and regulatory authorities to develop a strategy to provide its investigational compound, remdesivir, to patients with COVID-19 for emergency treatment in the absence of any approved treatment options, and to support clinical trials to determine whether it can safely and effectively be used to treat COVID-19. Together with health authorities in China, Gilead has initiated two clinical trials in patients who have been infected with COVID-19 to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus. Both trials are now enrolling participants. The company is also working with regulatory authorities to provide remdesivir to physicians for compassionate use to treat a small number of severely ill patients with confirmed COVID-19 infection and severe clinical symptoms. In anticipation of potential future needs, Gilead has accelerated manufacturing timelines to increase its available supply of remdesivir as rapidly as possible. This is being done before knowing whether remdesivir will be determined to be safe and effective to treat patients with COVID-19.

吉利德:吉利德与全球卫生组织合作,支持应对新冠肺炎大流行。该公司正在与政府、非政府组织以及监管机构合作制定策略,在尚无获批治疗方案的情况下,向需要紧急治疗的新冠肺炎患者提供研究性化合物瑞德西韦(remdesivir),并支持临床试验以确定瑞德西韦是否可以安全有效地用于治疗新冠肺炎。吉利德与中国卫生部门一起,开展两项在新冠感染患者中的临床试验,,以确定瑞德西韦作为冠状病毒潜在疗法的安全性和有效性。两项试验现在正在招募参与者。该公司还与监管机构合作,向医生提供瑞德西韦,以同情用药的方式,治疗少数临床症状严重的确诊新冠重症患者。考虑到潜在的未来需求,吉利德已加快生产进度,尽快增加其瑞德西韦的供应。这些工作将在确认瑞德西韦是否可以安全有效地治疗新冠肺炎患者之前完成。

GlaxoSmithKline: GlaxoSmithKline (GSK) is closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus. Since the outbreak, GSK has been actively exploring ways to help, with science and expertise, alongside protecting the health and wellbeing of its people and managing the company’s global supply chains to support patients and consumers who depend on GSK products. 

GSK is taking the following actions to support the global response to COVID-19:

  • Donating $10 million to WHO and the UN Foundation’s COVID-19 Solidarity Response Fund to support WHO and partners prevent, detect and manage the pandemic, particularly where the needs are the greatest. 

  • Expansion of vaccines collaborations – GSK is now working with five partner companies and research groups across the world, including in the USA and China. This builds on previous announcements regarding partnerships with the University of Queensland and Clover Biopharmaceuticals to make our vaccine adjuvant technology available to support their respective COVID-19 vaccine research programs. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced, and therefore contributing to the protection of more people.

  • GSK is entering a new collaborative research effort, the COVID-19 Therapeutics Accelerator, by making available compounds from its libraries for screening, with the aim of bringing forward the most promising molecules that could be used to treat cases of COVID-19.

  • Evaluating its marketed medicines and those in development, to determine if any could be used beyond their current indications, and evaluating options to make available specialized laboratory space to help in research and testing of COVID-19.

  • GSK is also donating surplus reagents to countries to support diagnostic testing, preparing to do the same for surplus personal protective equipment (PPE) and have initiated new volunteering processes for employees, to enable those with medical or specialist expertise to provide support to frontline health workers and national governments. 

GSK continues to monitor the situation closely, and take actions to develop our response to the pandemic. In doing so, we will continue to put the needs of patients and our people first at all times.

葛兰素史克:葛兰素史克(GSK)正密切关注2019冠状病毒病的流行情况,同时持续为全球抗击疫情提供支持。自疫情暴发以来,葛兰素史克一直在积极探索如何利用葛兰素史克在科学和医药领域的领先经验和专业知识来提供帮助,同时保护员工们的健康和安全,管理全球供应链,为依赖于我们产品的患者和消费者提供支持。

葛兰素史克正在采取以下行动来支持对COVID-19的全球响应:

  • 葛兰素史克向由联合国基金会和世卫组织共同成立的COVID-19团结应对基金捐赠1000万美元,支持世卫组织及其合作伙伴在需求最迫切的地方进行预防、检测并管理疾病大流行。
  • 扩大疫苗合作关系——葛兰素史克正与五家公司和研究机构开展合作,这些公司和机构来自于世界各地,包括中国和美国。这是基于先前宣布与昆士兰大学三叶草生物制药有限公司建立的合作关系,以使葛兰素史克的疫苗佐剂技术可用于支持各自的COVID-19疫苗研究计划。在发生疾病大流行的情况下,使用佐剂尤其重要,因为它可以减少每剂疫苗所需的疫苗蛋白量,从而能增加疫苗产量,保护更多人。
  • 葛兰素史克正进入一个全新的合作研究领域——COVID-19治疗加速器。这将使制药公司和专业学术机构协同参与到研究项目中,从而推进最有希望用于治疗2019冠状病毒病的药物分子研究。
  • 葛兰素史克正在评估已上市产品和在研药物,确定它们是否能在目前适应症范围以外发挥作用,以协助抗击疫情。其中包括具备潜在直接抗病毒作用的药物,以及可能用于防治2019冠状病毒病继发性并发症的药物。
  • 葛兰素史克还向各国捐赠了多余的试剂以支持诊断测试,准备对多余的个人防护设备(PPE)进行同样的处理,并启动新的员工志愿服务程序,以使具有医学或专业知识的人员能够为一线医疗工作者和政府提供支持。

葛兰素史克会继续密切关注疫情的变化,并采取进一步措施,对疾病大流行做出响应。在此过程中,葛兰素史克始终将患者和员工的需求放在首位。

Johnson & Johnson: Johnson & Johnson (J&J) is seeking to further expedite its investigational coronavirus vaccine programthrough an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services. 

The Company announced on March 30, 2020 the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the BARDA; and the rapid scaling of the Company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.

Through a landmark new partnership, BARDA, which is part of the Office of the ASPR at HHS, and Johnson & Johnson together have committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing. Johnson & Johnson will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts. Separately, BARDA and the Company have provided additional funding that will enable expansion of their ongoing work to identify potential antiviral treatments against the novel coronavirus.

Additionally, J&J initiated a review of known pathways in coronavirus pathophysiology to determine whether previously tested medicines can be used to help patients survive a COVID-19 infection and reduce the severity of disease in non-lethal cases. Johnson & Johnson has also announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) to support the development of a preventive vaccine candidate for COVID-19. The parties have commenced preclinical testing of multiple vaccine prospects, with the aim to identify by the end of the month a COVID-19 vaccine candidate for clinical trials.

In January 2020, Johnson & Johnson announced its support of frontline health workers through the Johnson & Johnson Center for Health Worker Innovation, committing $250M over 10 years. The Johnson & Johnson Family of Companies and the Johnson & Johnson Foundation are increasing that commitment by $50M for immediate COVID-19 response, primarily focused on supporting frontline health workers. The company also has donated over $3.7M in personal protective equipment for frontline health workers, including goggles, protective suits and masks and made product donations to countries, including South Korea, China, Italy and more. To learn more, visit www.jnj.com/coronavirus.

强生公司(Johnson&Johnson):强生正在积极拓展其现有与美国生物医学高级研究与发展管理局(BARDA)的合作,进一步加快其冠状病毒疫苗研发项目进展。BARDA隶属美国卫生与公共服务部的预防与响应副部长(ASPR)办公室。

2020年3月30日,强生宣布,已从化学结构体中成功筛选出一种新冠肺炎主要候选疫苗,这项工作自2020年1月就已启动;;强生旗下的西安杨森制药公司拓展与BARDA之间的合作关系; 公司的生产能力迅速提升,其目标是向全球提供超过10亿剂疫苗。 该公司期望在2020年9月之前开展主要候选疫苗的人体临床研究,预计首批新冠肺炎疫苗有望于2021年初获得紧急使用授权。与一般疫苗开发程序相比,这将大大加快了疫苗开发进程。

通过这一具有里程碑意义的新合作关系,BARDA和强生公司已承诺投资超过10亿美元,共同资助疫苗的研究,开发和临床测试。 强生将依托已验证的疫苗平台,并在全球范围内按需分配人员和基础设施等资源,以专注开展这些工作。另外,生物医学高级研究与发展管理局和强生提供了额外的经费,在现有工作以外,研究治疗新冠肺炎的潜在抗病毒疗法。

此外,强生公司开展对冠状病毒病理生理学中已知通路的综述研究,过往测试的药物是否有助于患者感染新冠病毒后幸存并降低非致死病例的疾病严重程度。 强生公司还宣布,旗下的西安杨森制药公司已与贝斯以色列女执事医疗中心(BIDMC)建立合作关系,开发针对新冠肺炎的预防性疫苗候选物。为了在月底前确定用于临床试验的新冠肺炎候选疫苗,双方已开始对多种疫苗的效果进行临床前测试。

2020年1月,强生公司宣布,通过强生医务工作者创新中心,10年内捐赠2.5亿美元,用于支持一线医护工作者。强生集团和强生基金会(Johnson&Johnson Foundation)将对于新冠肺炎应急响应的援助金额增加至5千万美元,主要用于支持一线医务工作者。 该公司还向一线医务工作者捐赠了超过价值370万美元的护目镜,防护服和口罩等个人防护物资,,并向韩国,中国,意大利等国家捐赠物资。 要了解更多信息,请访问www.jnj.com/coronavirus

Lundbeck: As an organization dedicated to improving the lives of people affected by brain diseases, with a particular focus on supporting the mental health of individuals across the globe, Lundbeck is working to support communities that may be most impacted by the COVID-19 outbreak. The company is taking action to bolster our health care system’s ability to respond to the pandemic. The Lundbeck US Charitable Fund made a significant donation to the Center for Disaster Philanthropy COVID-19 Response Fund, which focuses on nonprofit organizations working directly to support health care workers and respond to the pandemic among the most vulnerable populations. Lundbeck’s La Jolla Research Center donated a large portion of its inventory of disposable gloves to California healthcare workers in local area hospitals. Across the globe, the company’s local affiliates are supporting relief organizations; early in the pandemic, Lundbeck China donated 1 million Chinese Yuen to the Red Cross Foundation to support the front line workers in the city of Wuhan. And the Lundbeck Foundation, which owns 70% of Lundbeck, has earmarked DKK 30 million (USD 4.3 million) for research projects targeting the current coronavirus pandemic.  

灵北(Lundbeck):灵北是一个致力于改善患者受脑部疾病影响的生命的组织,重点支持全球范围内的个体心理健康。灵北正在支持那些最受新冠肺炎疫情影响的社区。该公司正在采取行动,以增强医疗卫生系统应对大流行的能力。灵北美国慈善基金向美国灾难慈善中心的新冠肺炎应急基金捐款,新冠肺炎应急基金主要针对那些直接支持医务工作者并帮助新冠大流行中的弱势群体的非营利组织。灵北的拉荷亚研究中心向当地医院中来自加州的医护人员捐赠了大部分库存的一次性手套。。在全球范围内,该公司的当地分支机构正在支持救济组织;在大流行初期,灵北中国向红十字基金会捐赠了100万元人民币,用于支持武汉一线医务工作者。拥有灵北70%股权的灵北基金会(Lundbeck Foundation)已拨款3000万丹麦克朗(折合430万美元)用于针对当前冠状病毒大流行的研究项目。

Merck: The company has provided a half a million (500,000) personal protective masks to New York City for use as part of urgent efforts to address the outbreak in New York. The company has also donated 300,000 masks for New Jersey. In response to the COVID-19 pandemic, Merck remains focused on protecting the safety of its employees and their families, assuring that our supply of medicines and vaccines reach our patients, contributing its scientific expertise to the development of antiviral approaches, and supporting its healthcare providers and the communities in which they serve.

默克(Merck):该公司向纽约市提供了五十万只个人防护口罩,用于紧急应对纽约疫情 该公司还为新泽西州捐赠了30万只口罩。 为了应对新冠肺炎大流行,默克始终专注于保护员工及其家人的安全,确保药物和疫苗供应覆盖到患者,为抗病毒研发贡献其科学专业知识,并支持医疗保健提供者及其服务的社区。

Novartis: Novartis has announced a broad range of initiatives to respond to COVID-19 Pandemic. Efforts include the creation of a $20 million global fund to support impacted communities and entering into new collaborative research efforts such as the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, as well as a COVID-19 directed partnership organized by the Innovative Medicines Initiative. The company has also made available a set of compounds from its libraries that it considers suitable for in vitro antiviral testing and is evaluating its existing products to see if any could be repurposed beyond their approved indications. The company will also donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts, and will evaluate needs for additional clinical trials. When supported for use in COVID-19 infected patients by regulatory authorities, Novartis intends to donate up to 130 million 200 mg doses by the end of May, including its current stock of 50 million 200 mg doses. The company is also exploring further scaling of capacity to increase supply and is committed to working with manufacturers around the world to meet global demand.

诺华:诺华宣布了一系列抗击新型冠状病毒肺炎大流行的举措。具体举措包括设立了一个2000万美元的全球基金,用以支持受疫情影响的社区;并开展新的合作研究工作,例如由比尔及梅琳达·盖茨基金会、惠康基金会和万事达公司联合推出的新冠肺炎治疗加速器平台,以及由欧洲创新药物计划(IMI)组织的COVID-19研发合作伙伴关系。同时,诺华还从其化合物库中筛选一组合适的化合物用于体外抗病毒测试,并正在评估其现有药物,以期寻找获批适应症之外的抗新冠病毒治疗的可能性。此外,诺华还将捐赠由其仿制药单元提供的高达1.3亿剂羟氯喹,以支持全球应对新冠肺炎疫情。羟氯喹及一款相关药物氯喹目前正在被用于临床试验,以评估治疗新冠肺炎的疗效。诺华支持正在进行的临床试验,并将评估是否需要进行额外的临床试验。若监管机构支持将该药物用于治疗新冠肺炎感染的患者,诺华计划在5月底之前捐赠高达1.3亿剂羟氯喹200 mg剂量),包括其当前库存的5000万剂羟氯喹(200 mg剂量)。诺华还在探索进一步扩大产能,以增加供应,并致力于与全球各地的生产商合作,以满足全球需求。

Pfizer: The company has recently completed a preliminary assessment of certain antiviral compounds  that were previously in development and that inhibited the replication of coronaviruses similar to the one causing COVID-19 in cultured cells. Pfizer is engaging with a third party to screen these compounds under an accelerated timeline and currently expects to have the results back by the end of March. Upon completion of such screening, the company could be in a position to move forward with development depending on the results. Toxicology studies would then need to be completed prior to any clinical development, but if successful, Pfizer hopes to be in the clinic by no later than the end of 2020.

Additionally, Pfizer and BioNTech announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together. The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020. The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza. 

Furthermore, in the United States, the Pfizer Foundation has provided a $500,000 grant to International Medical Corps. The funding will support the provision of urgently needed supplies to front-line health care workers, provide training, and deploy medical strike teams. Pfizer Inc has also donated select antibiotics to Direct Relief to manage complications related to COVID-19.

辉瑞:辉瑞最近完成了一些抗病毒化合物的初步评估,这些化合物先前正在开发中,并被发现能抑制与培养细胞中生成的与新冠病毒相似的冠状病毒的复制。辉瑞正在与第三方合作,加快筛选这些化合物的时间进度,目前预计在3月底之前可以得到结果。筛选完成后,公司将根据筛选结果决定是否继续研发。接下来的毒理学研究将需要在临床试验之前完成,如果试验成功,辉瑞希望在2020年底前进入临床。

辉瑞和BioNTech还宣布,两家公司已就共同开发和分销一种潜在的基于mRNA的冠状病毒疫苗达成意向书,以预防COVID-19感染(不包括中国市场)。两家公司已经签署了一份材料转让与合作协议,以便双方立即开始合作。这项合作旨在加速BioNTech这一潜在的COVID-19 mRNA疫苗计划BNT162的开发,该计划有望在2020年4月底进入临床试验。这项合作的快速发展基于辉瑞和BioNTech此前于2018年开始的合作,双方共同开发用于预防流感的mRNA疫苗。

此外,在美国,辉瑞基金会向国际医疗队(IMC)提供了50万美元的捐款。这笔资金将支援一线医护人员,为其提供急需物资,培训和部署医疗突击队伍。辉瑞还向国际直接援助组织(Direct Relief)捐赠了一批选定的抗生素,以治疗与新冠肺炎相关的并发症。

Sanofi: Sanofi Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi is collaborating with BARDA, expanding the company’s long-standing partnership with the Authority. Sanofi will use its recombinant DNA platform to produce a 2019 novel coronavirus vaccine candidate. The recombinant technology produces an exact genetic match to proteins found on the surface of the virus. The DNA sequence encoding this antigen will be combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product, and used to rapidly produce large quantities of the coronavirus antigen which will be formulated to stimulate the immune system to protect against the virus.  

赛诺菲:赛诺菲巴斯德(法国制药公司赛诺菲旗下全球疫苗事业部)将利用公司先前开发非典型肺炎(SARS)疫苗所积累的经验,加速COVID-19疫苗研发。在赛诺菲与BARDA建立长期合作伙伴关系的基础上,赛诺菲将继续与BARDA拓展合作。赛诺菲将利用其基因重组技术平台开发2019新型冠状病毒候选疫苗,该技术平台能对病毒表面的蛋白质产生精确的基因匹配。DNA序列编码将被结合到杆状病毒表达平台的DNA中,并用于快速制造大量的冠状病毒抗原,这些抗原经配制后讲刺激人体免疫系统来抵御病毒。赛诺菲利用杆状病毒表达平台开发了一款重组流感疫苗产品,该产品已获批上市。

Takeda: Takeda is developing of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) with the potential to treat high-risk individuals with COVID-19, which is being referred to as TAK-888.  Hyperimmune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections.  Takeda is currently in discussions with multiple national health and regulatory agencies and health care partners in the US, Asia, and Europe to expeditiously move the research into TAK-888 forward. In addition, Takeda is exploring whether select marketed therapies and molecules in its drug library could be viable candidates for the effective treatment of COVID-19. These efforts are at an early stage but being given a high priority within the company.   

Takeda is also donating more than $6.25 million dollars to organizations in the United States to help those impacted by the Coronavirus and to help enable organizations to continue helping the communities they serve.

武田:武田正在开展武田将启动研发抗新冠病毒(SARS-CoV-2)多克隆高免疫球蛋白(H-IG)以用于治疗高危COVID-19患者,也被称为TAK-888。高免疫球蛋白是血浆来源的治疗方法,先前已被证明在治疗严重急性病毒性呼吸道感染方面有效。武田正在同美国、亚洲和欧洲多国家的卫生监管机构讨论,以迅速推进TAK-888研究项目。此外,武田正在探索其药物库中精选的上市疗法和分子是否可能成为有效治疗COVID-19的可行候选药物。这些努力还处于早期阶段,但在公司内部得到了高度重视。武田还向美国的一些组织捐赠了625万美元,帮助这些组织继续支持他们所服务的社区。

Teva Pharmaceutical: Teva is donating critical medicines, which are being studied in clinical trials to assess benefit against COVID-19 globally, including more than 10 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. This includes tablets being used in critical research efforts. TEVA’s global manufacturing network continues to increase production of both active pharmaceutical ingredients (API) and finished product to ensure these medicines will get to patients globally, wherever and whenever they are needed.

梯瓦制药:梯瓦制药将捐赠重要药物,包括通过批发商向美国各地医院提供1000多万剂硫酸羟基氯喹片。这些药物目前正被用于临床试验,以评估在全球范围内对COVID-19的疗效。梯瓦制药全球制造链持续增加原料药(API)和成品药的生产,以确保这些药物将及时惠及全球各地的患者,无论何时何地。

The biopharmaceutical industry has the capacity and expertise to find and scale solutions to prevent and treat infection of the coronavirus and we will continue to provide updates on the response to the outbreak, and our member companies’ contributions, as the situation evolves.

生物制药行业拥有足够的专业能力和知识储备,以找到并普及预防和治疗冠状病毒感染解决方案。随着疫情的进展,我们将持续更新应对疫情的最新信息,并分享成员公司为抗击疫情所做出努力与贡献。

To learn more about biopharmaceutical efforts to combat coronavirus, visit PhRMA.org/Coronavirus 

更多详情,请访问PhRMA.org/Coronavirus